Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   * Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management    * Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases    * High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities.      This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0 [https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0]    Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2 [https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2]     Follow us on social media:  LinkedIn: https://linkedin.com/company/ntrk-connect [https://linkedin.com/company/ntrk-connect]  X: https://x.com/PresOnc_Connect [https://www.youtube.com/redirect?event=video_description&redir_token=QUFFLUhqbkt4QUQwYlhJTjFzUE9rTmlFeWdDNVRvQ0VMQXxBQ3Jtc0trYmhvLU1PNVYweDVBRVNPaUZsLTVIVGtwVl9wQklOa0tNc0RldGhRN0xUeHcxQjEzejhLc2V0TEpjNUNWVktnNW5IU19PaFU1TDgxYXlaTEZkNm9HNkFQNzlCNzlRaDZZWTltRVpzR1V6Rjdvbkdocw&q=https%3A%2F%2Fx.com%2FPresOnc_Connect&v=7BNHwXvh4lw]    This content is intended for healthcare professionals only.   This video is supported by an Independent Education Grant from Daiichi Sankyo.    This video is developed by cor2ed.com  Published on March 2026.    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice. The experts explore: * Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework * The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template * When and why to perform re-biopsy to detect changes in HER2 expression over time * Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis   Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.   Clinical takeaways   * DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd * Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd * Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd * T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment       This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw [https://youtu.be/3xepcF70Ljw]   Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website   Follow us on social media: LinkedIn: https://www.linkedin.com/company/breastcancerconnect/ [https://www.linkedin.com/company/breastcancerconnect/] X: https://x.com/BreastCaConnect [https://x.com/BreastCaConnect]   This content is intended for healthcare professionals only.   This programme is supported by an Independent Education Grant from AstraZeneca. This podcast is developed by cor2ed.com   Published December 2025   Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.   They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.   Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.  Key clinical takeaways:   * Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments * While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise  * Accessing a support network can provide emotional reinforcement and information for patients and their care partners    You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0  Or watch on YouTube: https://youtu.be/nfng2s3jSw8  Follow us on social media:  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true [https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true]   X:https://x.com/net_connectinfo [https://x.com/net_connectinfo]  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim. This podcast is developed by cor2ed.com  Published in November 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Exploring the role of targeted radiopharmaceutical treatment in NETs

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?  In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.  As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.  Key clinical takeaways:   * Pair the right patient with the right treatment using an understanding of the key clinical studies  * The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data   * The best outcomes are achieved through multi-disciplinary collaborations that include the patient     Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0 [https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0]   Follow us on social media:  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true [https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true]   X: https://x.com/net_connectinfo [https://x.com/net_connectinfo]   This content is intended for healthcare professionals only.  This podcast is supported by an Independent Education Grant from ITM.   This podcast is developed by cor2ed.com    Published September 2025

Tackling mPDAC: chemotherapy strategies that matter

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.    This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.  Key clinical takeaways:  * mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible * Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles * Choice of 2nd line treatment should be guided by prior regimen and patient fitness * Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0 [https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0]  Or watch on YouTube: https://youtu.be/8YxRnjOYUv4 [https://youtu.be/8YxRnjOYUv4]  Follow us on social media:  LinkedIn: https://www.linkedin.com/company/giconnect [https://www.linkedin.com/company/giconnect]  X: https://x.com/giconnectInfo [https://x.com/giconnectInfo]  This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen USA.  This podcast is developed by cor2ed.com  Published May 2025  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.